Literature DB >> 10509982

Integrated left anterior small thoracotomy and angioplasty for coronary artery revascularization.

C T Lloyd1, A M Calafiore, P Wilde, R Ascione, L Paloscia, C R Monk, G D Angelini.   

Abstract

BACKGROUND: The minimal access surgical technique of a left anterior small thoracotomy (LAST) for coronary artery bypass grafting is now well established. This procedure however, does not allow multivessel revascularization. We present our early experience of an integrated approach using LAST and percutaneous transluminal coronary angioplasty (PTCA), either staged or simultaneous.
METHODS: Eighteen patients (14 men and 4 women), mean age 63 (range 35-87 years) were treated. Four patients underwent simultaneous LAST and PTCA revascularization. The remaining 14 patients were first treated with the LAST procedure, followed 1-3 days later by angioplasty. Angiographic assessment was carried out before PTCA and at 6 months after.
RESULTS: The 14 patients who underwent the staged procedure all had patent left internal mammary artery/left anterior descending coronary artery grafts. Angioplasty was performed on 21 vessels (10 stented) with good early angiographic results. All patients were extubated early, mean intensive care stay was 14.7 + 9.4 hours, mean hospital stay was 5 + 1.5 days. All patients were symptom free at 18 months follow-up.
CONCLUSIONS: Staged LAST and angioplasty is a safe and effective approach suitable for patients in whom there are contraindications to the use of extracorporeal circulation. The simultaneous approach is limited by the risk of bleeding associated with the use of anticoagulation when coronary stenting is required.

Entities:  

Mesh:

Year:  1999        PMID: 10509982     DOI: 10.1016/s0003-4975(99)00555-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Hybrid revascularization feasibility in minimally invasive direct coronary artery bypass grafting combined with percutaneous transluminal coronary angioplasty in patients with acute coronary syndrome and multivessel disease.

Authors:  Y Matsumoto; M Endo; F Kasashima; Y Abe; I Kosugi; Y Hirano; H Sasaki; T Ueyama
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-12

Review 2.  Status quo of hybrid coronary revascularization for multi-vessel coronary artery disease.

Authors:  Ralf E Harskamp; Zhe Zheng; John H Alexander; Judson B Williams; Ying Xian; Michael E Halkos; J Matthew Brennan; Robbert J de Winter; Peter K Smith; Renato D Lopes
Journal:  Ann Thorac Surg       Date:  2013-12       Impact factor: 4.330

Review 3.  Combining PCI and CABG: the role of hybrid revascularization.

Authors:  Kelly D Green; Donald R Lynch; Tyffany P Chen; David Zhao
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

4.  Hybrid approach for complex coronary artery and valve disease: a clinical follow-up study.

Authors:  J O J Peels; G A J Jessurun; P W Boonstra; T Ebels; D J van Veldhuisen; I C C van der Horst; F Zijlstra
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

5.  Bivalirudin as an anticoagulant for simultaneous integrated coronary artery revascularization - a novel approach to an inherent concern.

Authors:  R Scott McClure; Jennifer Higgins; Stuart A Swinamer; Reiza Rayman; Wojciech B Dobkowski; William J Kostuk; Bob Kiaii
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

6.  The curative effect of synthetic treatment for refractory acute myocardial infarction.

Authors:  Jing Xie; Ding-Xiong Xie; Yi-Rong Gan; Jiong Li; Yan-Zhen Wang; Zong-Ke Kou; Rui Mao; Tian-Xiang Liang; Yun-Long Zhang
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

7.  Hybrid coronary revascularization as a safe, feasible, and viable alternative to conventional coronary artery bypass grafting: what is the current evidence?

Authors:  Arjan J F P Verhaegh; Ryan E Accord; Leen van Garsse; Jos G Maessen
Journal:  Minim Invasive Surg       Date:  2013-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.